Analytical Data
-
Gene name
A2LD1
- Application
-
Alternative Names
GGACT;A2LD1;gamma-glutamyl cyclotransferase;GGACT;EC 4.3.2.8
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BVM4
-
Expression Region
1-153aa
-
AA Sequence
MALVFVYGTL KRGQPNHRVL RDGAHGSAAF RARGRTLEPY PLVIAGEHNI PWLLHLPGSG RLVEGEVYAV DERMLRFLDD FESCPALYQR TVLRVQLLED RAPGAEEPPA PTAVQCFVYS RATFPPEWAQ LPHHDSYDSE GPHGLRYNPR ENR
-
Molecular Weight
19 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
A2LD1 is a member of the A2-like superfamily of proteins, which has garnered attention due to its potential role in various biological processes, including immune response and cellular signaling pathways. Research indicates that A2LD1 may play a crucial role in the regulation of inflammatory responses and may be implicated in several diseases, including autoimmune disorders and cancer. The protein’s structure and function are not yet fully understood, making it a prime target for further investigation. Advances in recombinant DNA technology have enabled researchers to produce A2LD1 in vitro, allowing for detailed studies of its biochemical properties, interactions, and potential therapeutic applications. By elucidating the mechanisms by which A2LD1 operates, scientists hope to uncover new insights into its role in health and disease, potentially leading to novel treatment strategies. The study of A2LD1 is particularly relevant given the increasing need for targeted therapeutic approaches in precision medicine, as well as the ongoing search for biomolecules that can modulate immune responses effectively. Continued research into A2LD1 and its recombinant forms will not only enhance our understanding of this protein but also contribute to broader efforts in drug discovery and the development of innovative treatments for various health conditions.
